Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

URN to cite this document:: urn:nbn:de:bvb:355-epub-360831
DOI to cite this document:: 10.5283/epub.36083

Tak, P. P. ; Rigby, W. F. ; Rubbert-Roth, A. ; Fleck, Martin

Preview

License: Allianz- bzw. Nationallizenz
PDF - Published Version
(262kB)

Date of publication of this fulltext: 08 Aug 2017 08:26

Alternative links to fulltext:DOI

Details

Preview

Export bibliographical data

Abstract

Objectives: Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX. Methods: In this double-blind randomised controlled phase III study, 755 MTX-naïve ...